You are being redirected because this document is part of your ASTM Compass® subscription.
    This document is part of your ASTM Compass® subscription.

    Volume 46, Issue 4 (July 2001)

    GHB and Driving Impairment

    (Received 15 May 2000; accepted 22 August 2000)


      Format Pages Price  
    PDF (268K) 5 $25   ADD TO CART

    Cite this document

    X Add email address send
      .RIS For RefWorks, EndNote, ProCite, Reference Manager, Zoteo, and many others.   .DOCX For Microsoft Word


    Gamma hydroxybutyrate (GHB) was identified in the blood of 13 subjects arrested for impaired driving. GHB concentrations ranged from 26 to 155 mg/L (mean 87 mg/L, median 95 mg/L). In eight cases, GHB was the only drug detected, and signs of impairment were consistent with those of a CNS depressant, including erratic driving (weaving, swerving, ignoring road signs), confusion, incoherent speech, unresponsiveness, lack of balance, unsteady coordination, poor performances on field sobriety tests, and varying states of wakefulness. Given the ability of GHB to induce sleep and unconsciousness, it is evident from these cases that recreational use of the drug has the potential to impair a person's driving ability.

    Author Information:

    Logan, BK

    Couper, FJ
    Washington State Toxicology Laboratory, University of Washington, Seattle, WA

    Stock #: JFS15070J


    DOI: 10.1520/JFS15070J

    Title GHB and Driving Impairment
    Symposium ,
    Committee E30